FilingSEC EDGAR8-K
Alzamend Neuro Presents Phase 1/2A Clinical Trial Data for AL001
· SEC accepted
StagePhase 1/2A
Filing content
Alzamend Neuro presented initial Phase 1/2A clinical trial data for AL001 at an international conference. The current results are not statistically significant, and the company plans to conduct further studies in patient cohorts.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…